Prostate-specific Membrane Antigen PET/Computed Tomography in Prostate Cancer : Staging, Restaging, Interpretation, and Clinical Management - 04/09/26
Doi : 10.1016/j.rcl.2026.07.004
Ridvan A. Demirci, MD a, Amir Iravani, MD b, c, d, ⁎ 
a Department of Radiology, University of Iowa Health Care, Iowa City, IA, USA
b Department of Radiology, University of Washington, Seattle, WA, USA
c Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA
d Department of Nuclear Medicine and Theranostics, University of California Los Angeles, Los Angeles, CA, USA
∗ Corresponding author. Department of Radiology, University of Washington, Seattle, WA. Department of Radiology University of Washington Seattle WA
In corso di stampa. Prove corrette dall'autore.
Disponibile online dal Friday 04 September 2026
Riassunto |
Prostate-specific membrane antigen (PSMA) PET/computed tomography has transformed prostate cancer imaging, offering superior diagnostic accuracy over conventional modalities. This article provides radiology professionals with a practical guide to available PSMA PET agents, interpretation, appropriate use criteria, standardized reporting frameworks, and common interpretation pitfalls.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Prostate-specific membrane antigen, PSMA PET/CT, Prostate cancer staging, Biochemical recurrence, PSMA radiotracers, Standardized reporting
Mappa
© 2026
Elsevier Inc. Tutti i diritti riservati.
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?